FCT certified as a B Corporation, meeting strict social and environmental standards

Groundbreaking software company improving the lives of foster children commits to rigorous standards of social and environmental performance, accountability and transparency. Lawrence, KS  – January 2, 2018 – Foster Care Technologies (FCT), provider of the world’s only scientific, data-driven software for improving placements of children in foster homes, today announced that it has officially become a Certified B Corporation. B Corporations must pass an exhaustive assessment that reviews their commitment to improving communities, the natural environment and society through their businesses practices. FCT joins the rapidly growing movement of more than 2,300 Certified B Corporations from 121 industries, across 40…
Read the full article

Doing Their Research

by David Mitchell Vol. 27 Issue 2 Lisa Stehno-Bittel apparently has a pretty good poker face. During the first year of running Likarda, the biotech startup she co-founded, a new employee eyed the company’s president and offered a blunt assessment of the academic turned entrepreneur. “Leading people is a lot of what goes into a business,” he said. “She had experience leading people and built a successful program—one of the top 10 programs in the country.” Ramachandran said the researchers understood their blind spots and hired legal and financial firms to help. They also had help building a business plan from…
Read the full article

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic Imaging

January 18, 2018 Focus will be on hospital-based products that could benefit from reduced renal toxicity Leverages Captisol® and new intellectual property from Verrow Pharmaceuticals acquisition SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces initiation of a program to develop contrast agents with reduced renal toxicity. Contrast agents are injectable solutions used during diagnostic imaging procedures. Through this new, internally-funded program, Ligand intends to advance products toward proof-of-concept, followed by selling or out-licensing them for further development and commercialization. The program will leverage Ligand’s patented Captisol® technology, as well as data and intellectual property obtained through its acquisition of…
Read the full article

On a list of best performing cities in America, Lawrence takes a big leap

Posted by Chad Lawhorn January 11, 2018 at 1:02 p.m. On this wintry mix of a day — with schools canceled and many businesses letting “non-essential employees” stay home — Lawrence would rank high in the number of people eating cereal in bed, parents desperately searching for earplugs, and people feeling good about being non-essential. I have news about another ranking, though. For the first time in a while, Lawrence has scored well in a respected ranking of the best-performing small cities. Lawrence checked in at No. 41 out of 201 small metro areas ranked by the Milken Institute in its 2017…
Read the full article

Ligand Earns $6 Million as OmniAb Partner Out-Licenses Antibody Projects

January 3, 2018 Raises 2017 Guidance SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner HanAll Biopharma successfully out-licensed antibody projects that were discovered by HanAll using Ligand’s OmniAb® antibody discovery platform. The licensing events triggered $6 million of payments to Ligand. HanAll has had access to the OmniAb platform since December 2014 and is developing multiple antibody projects in the immunno-oncology and autoimmune areas using this platform. Under the license agreements with HanAll, Ligand is eligible to receive milestones and royalties on the successful development of antibodies and to share sub-license revenue on outlicensed antibodies. “These…
Read the full article

Next

Ready to take your technology to the masses? Let’s do business.